Antibiotic Accelerator From BARDA Nears Investment Stage
This article was originally published in The Pink Sheet Daily
Federal funding could pay to help early antibiotic discovery efforts with 'fragile' pipeline still struggling.
You may also be interested in...
FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.
Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.
David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.